Skip to search formSkip to main contentSkip to account menu

CNTO 530

Known as: CNTO-530 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Recombinant Fusion Proteins

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
A Novel EPO Receptor Agonist Improves Glucose Tolerance via Glucose Uptake in Skeletal Muscle in a Mouse Model of Diabetes
Patients treated with recombinant human Epo demonstrate an improvement in insulin sensitivity. We aimed to investigate whether… 
2011
2011
Pharmacodynamics of CNTO 530 and Darbepoetin-α in Human TNF-α Transgenic Mice, a Murine Model of Anemia of Chronic Disease
CNTO 530 and darbepoetin-a are long lived erythropoietin receptor agonists (ERAs). Clinically, anemia of chronic disease (ACD) is… 
2010
2010
Pharmacokinetics and Pharmacodynamics of an EPO-Mimetic Fusion Protein in a Model of Chronic Renal Insufficiency Anemia
Renal insufficiency is commonly associated with an erythropoietin (EPO) dependent anemia. CNTO 530 is an EPO-mimetic antibody… 
2009
2009
CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools.
Anemia as associated with numerous clinical conditions can be debilitating, but frequently can be treated via administration of… 
2008
2008
CNTO 530: molecular pharmacology in human UT-7EPO cells and pharmacokinetics and pharmacodynamics in mice.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)